Fig. 4From: Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab—a pilot studyCentral retinal volume (mean, SD): change from baseline to month 12 (p = 0.021)Back to article page